Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 7;10(5):00561-2024.
doi: 10.1183/23120541.00561-2024. eCollection 2024 Sep.

Corticosteroid therapy in fibrotic interstitial lung disease: a modified Delphi survey

Manuela Funke-Chambour  1 , Philipp Suter  1 , Gisli R Jenkins  2 , Leticia Kawano-Dourado  3 , Christopher J Ryerson  4 , Athol U Wells  5 , Michael Kreuter  6   7   8 , Kerri A Johannson  9   8 ; Delphi Survey Participants
Affiliations

Corticosteroid therapy in fibrotic interstitial lung disease: a modified Delphi survey

Manuela Funke-Chambour et al. ERJ Open Res. .

Abstract

The use of steroids in fibrotic interstitial lung diseases is founded on limited evidence. This modified Delphi survey sheds light on current clinical practices. Given the risks of steroids, clinical trials are needed to evaluate efficacy and harm. https://bit.ly/3VkgvbS.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: M. Funke-Chambour declares grants or contracts from Boehringer Ingelheim, consultancy and speaker's fees from Boehringer Ingelheim, Roche, MSD, AstraZeneca, Pfizer, GSK and Sanofi, outside this project. P. Suter has nothing to disclose. G.R. Jenkins declares grants to his institution from AstraZeneca, Biogen, Galecto, GlaxoSmithKline, Nordic Biosciences, RedX and Pliant, consultancy fees from AbbVie, Apollo Therapeutics, AstraZeneca, Brainomix, Bristol Myers Squibb, Chiesi, Cohbar, Daewoong, GlaxoSmithKline, Resolution Therapeutics and Pliant, honoraria from Boehringer Ingelheim, Chiesi, Roche, PatientMPower and AstraZeneca, payment for expert testimony from Pinsent Masons LLP, and participation on data safety or advisory board for Boehringer Ingelheim, Galapagos and Vicore, outside this project. L. Kawano-Dourado declares grants paid to their institution from Boehringer Ingelheim and Bristol Myers Squibb, and consultancy fees from Boehringer Ingelheim, outside this project. C.J. Ryerson declares grants from Boehringer Ingelheim paid to his institution, consultancy fees from Boehringer Ingelheim, Pliant Therapeutics, AstraZeneca, Trevi Therapeutics and Veracyte, payment or honoraria for lectures or presentations from Hoffmann-La Roche and Boehringer Ingelheim, and payment for expert testimony and travel support from Boehringer Ingelheim, outside this project. A.U. Wells reports consultancy fees from Roche, and payment or honoraria for lectures or presentations from Boehringer Ingelheim and Veracyte, and is President of the World Association of Sarcoidosis and Other Granulomatous Diseases, outside of the submitted work. M. Kreuter declares grants or contracts and royalties or licenses from Boehringer Ingelheim and Roche, consulting fees from Nichtraucherhelden/Sanero, Boehringer Ingelheim, Roche, BMS, GSK and AstraZeneca, and a leadership or fiduciary role for the European Respiratory Society, outside this project. K.A. Johannson declares grants paid to her institution from the University Hospital Foundation and the Three Lakes Foundation, consulting fees from Boehringer Ingelheim, Roche, Pliant Therapeutics and Brainomix, payment or honoraria for lectures or presentations and travel support from Boehringer Ingelheim, participation on a Data Safety Monitoring Board for the PFOX trial, and a stock option from Thyron SAB, outside this project.

Figures

FIGURE 1
FIGURE 1
Overview of the survey statements that were evaluated by the participants. fILD: fibrotic interstitial lung diseases; CT: computed tomography; HRCT: high-resolution CT; BAL: bronchoalveolar lavage; DLCO: diffusing capacity of the lung for carbon monoxide; GGO: ground glass opacity; MDA5: melanoma differentiation-associated protein 5.
See this image and copyright information in PMC

References

    1. Koudstaal T, Funke-Chambour M, Kreuter M, et al. . Pulmonary fibrosis: from pathogenesis to clinical decision-making. Trends Mol Med 2023; 29: 1076–1087. doi: 10.1016/j.molmed.2023.08.010 - DOI - PubMed
    1. Pitre T, Kawano-Dourado L, Kachkovski GV, et al. . Systemic corticosteroids in fibrotic lung disease: a systematic review and meta-analysis. BMJ Open Respir Res 2023; 10: e002008. doi: 10.1136/bmjresp-2023-002008 - DOI - PMC - PubMed
    1. Idiopathic Pulmonary Fibrosis Clinical Research Network , Raghu G, Anstrom KJ, et al. . Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968–1977. doi: 10.1056/NEJMoa1113354 - DOI - PMC - PubMed
    1. Behr J, Salisbury ML, Walsh SLF, et al. . The role of inflammation and fibrosis in interstitial lung disease treatment decisions. Am J Respir Crit Care Med 2024; 210: 392–400. 10.1164/rccm.202401-0048PP. - DOI - PubMed
    1. Meyer KC, Raghu G, Baughman RP, et al. . An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012; 185: 1004–1014. doi: 10.1164/rccm.201202-0320ST - DOI - PubMed

LinkOut - more resources